3 Αποτελέσματα
FIELD OF THE DISCLOSURE
The present disclosure relates to compositions and methods for the treatment of disorders associated with neuronal degeneration. More specifically, the present disclosure relates to of a mutant form of erythropoietin (EPO) for the treatment of disorders associated with
FIELD OF THE DISCLOSURE
The present disclosure relates to compositions and methods for the treatment of disorders associated with neuronal degeneration. More specifically, the present disclosure relates to of a mutant form of erythropoietin (EPO) for the treatment of disorders associated with
II.1. Chronic renal failure
II.2. Acute renal failure
II.3. Chronic or acute hepatopathy occurring with hyperammonemia
II.4. Congenital diseases with enzymatic alterations of the urea cycle
II.5. Pathological human conditions having negative nitrogen balance, namely:
II.5.1. Sepsis
II.5.2.